Company profile
Addimmune
HIV-focused gene/cell therapy business spun out of American Gene Technologies; a SPAC merger with 10X Capital Venture Acquisition Corp. III was announced Aug 2023 targeting a Q1 2024 close, but SEC EDGAR shows no completed rename/relisting under the shell company CIK as of this check, and no live quote exists for the reported ticker HIV on any exchange -- treated as still private/merger-not-confirmed-closed rather than trusting secondary press coverage.
Privately held: no public share price
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
AGT103-TNo recent activity | Phase 1 | HIV proviral reservoir / autologous T cellsGene therapy / editing | HIV |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.